{"id":179948,"date":"2026-02-08T21:26:51","date_gmt":"2026-02-09T02:26:51","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=179948"},"modified":"2026-02-08T21:26:51","modified_gmt":"2026-02-09T02:26:51","slug":"kims-hospitals-posts-strong-revenue-growth-in-q3-fy26-profitability-impacted-by-financing-costs-and-expansion-investments","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/kims-hospitals-posts-strong-revenue-growth-in-q3-fy26-profitability-impacted-by-financing-costs-and-expansion-investments\/","title":{"rendered":"KIMS Hospitals Posts Strong Revenue Growth in Q3 FY26, Profitability Impacted by Financing Costs and Expansion Investments"},"content":{"rendered":"\n<p>Krishna Institute of Medical Sciences Ltd (NSE:KIMS), a leading multi-specialty hospital chains, reported strong revenue growth in the third quarter of FY26 and the nine months ended December 31, 2025, driven by rising patient volumes, improved pricing metrics and capacity expansion across key regions, according to its latest investor presentation.<\/p>\n\n\n\n<p>KIMS operates a network of multi-specialty hospitals offering advanced tertiary and quaternary care across specialties including cardiology, oncology, neurology and organ transplantation. The group has expanded into multiple states including Andhra Pradesh, Maharashtra, Kerala and Karnataka, with a capacity exceeding 9,100 beds and a strategy focused on affordable, technology-driven healthcare delivery.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Key Financial Highlights \u2013 Q3 and 9M FY26<\/strong><\/h2>\n\n\n\n<p>Q3 FY26<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Operating revenue of \u20b99,977 million, up 29.2% year-on-year<\/li>\n\n\n\n<li>Total revenue rose 26.9% to \u20b910,029 million.<\/li>\n\n\n\n<li>EBITDA stood at \u20b92,041 million with a margin of 20.4%.<\/li>\n\n\n\n<li>Profit after tax declined to \u20b9519 million due to higher finance costs, depreciation and fair value adjustments.<\/li>\n<\/ul>\n\n\n\n<p>9M FY26<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Total revenue grew 25.6% year-on-year to \u20b928,465 million.<\/li>\n\n\n\n<li>EBITDA remained stable at around \u20b96,120 million<\/li>\n\n\n\n<li>PAT fell 32.3% to \u20b92,089 million.<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"548\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/KIMS-1024x548.png\" alt=\"\" class=\"wp-image-179950\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/KIMS-1024x548.png 1024w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/KIMS-300x161.png 300w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/KIMS-768x411.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/02\/KIMS.png 1152w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Operational Metrics<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Operational performance remained robust with Q3 inpatient volume rising 13.2% year-on-year to 61,139 and outpatient visits increasing 24.5% to 585,491.<\/li>\n\n\n\n<li>Average revenue per occupied bed climbed 20.5% to \u20b946,341, reflecting improved case mix and pricing.<\/li>\n\n\n\n<li>Bed capacity expanded to 6,464 beds in 9M FY26, supported by new facilities and expansions across regions.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Operational &amp; Business Highlights<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>KIMS continued investing in advanced robotic surgery, organ transplant programs and digital tools to enhance patient experience.<\/li>\n\n\n\n<li>Strategic acquisitions and turnaround initiatives improved operational efficiencies, while new specialty additions and recruitment of senior clinicians strengthened clinical capabilities.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Revenue &amp; Payor Mix Insights<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Cash pay patients contribute 53% of revenue, insurance 30%, corporate 13% and government schemes 4%.<\/li>\n\n\n\n<li>Specialty mix led by cardiac sciences (17%), orthopaedics (14%) and neurosciences (11%).<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Capacity Expansion &amp; Infrastructure Pipeline<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The company benefits from increasing healthcare demand in India, growth in high-end procedures, rising insurance penetration and a shift toward organized hospital chains.<\/li>\n\n\n\n<li>Increasing ARPOB and ARPP trends indicate stronger monetization amid improving healthcare utilization.<\/li>\n\n\n\n<li>Total operational beds increased to 4,825 in 9M FY26, reflecting rapid expansion.<\/li>\n\n\n\n<li>Multiple greenfield projects and planned hospitals, including Chennai (planned ~300 beds) and several expansions in Karnataka and Kerala.<\/li>\n\n\n\n<li>Target to add 2,000+ beds through acquisitions, greenfield developments and O&amp;M partnerships.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Clinical &amp; Technology Highlights<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>KIMS highlighted multiple clinical \u201cfirsts,\u201d including pioneering robotic procedures and advanced transplant surgeries, and maintained leadership in organ transplantation and specialized treatments in several regions.<\/li>\n\n\n\n<li>Deployment of advanced robotic systems, MRgFUS, TULSA-PRO and digital LINAC for precision care.<\/li>\n\n\n\n<li>Milestones include first robotic renal transplant in North Malabar and multiple complex transplant procedures completed in new facilities.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Growth &amp; Strategy Signals<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Strong historical performance with ~27% revenue CAGR and ~30% EBITDA CAGR over two decades.<\/li>\n\n\n\n<li>Strategic doctor equity partnerships and AI-enabled patient financial counselling tools to enhance retention and operational efficiency.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Management Commentary &amp; Strategy<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Management emphasized sustained growth driven by capacity additions, technology investments and doctor partnerships.<\/li>\n\n\n\n<li>The company plans to add over 2,000 beds through greenfield projects, acquisitions and operational management agreements, supporting long-term expansion.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Market Sentiment &amp; Outlook<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Remains positive due to consistent revenue growth, although investors are monitoring margin pressures from expansion costs.<\/li>\n\n\n\n<li>The company reiterated focus on scaling operations, improving occupancy and leveraging advanced medical technology to drive future growth.<\/li>\n\n\n\n<li>Strong community outreach initiatives and Panchayat partnerships to boost regional awareness.<\/li>\n\n\n\n<li>Increasing international patient referrals, particularly from African countries.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Krishna Institute of Medical Sciences Ltd (NSE:KIMS), a leading multi-specialty hospital chains, reported strong revenue growth in the third quarter of FY26 and the nine months ended December 31, 2025, driven by rising patient volumes, improved pricing metrics and capacity expansion across key regions, according to its latest investor presentation. KIMS operates a network of [&hellip;]<\/p>\n","protected":false},"author":2378,"featured_media":125269,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[5,1941,392,5747],"tags":[13743,15937,15936,10089],"class_list":["post-179948","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest","category-stock-analysis","category-earnings","category-healthcare-stocks","tag-health-care","tag-hospital-results","tag-kims","tag-quarterly-earnings"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":154796,"url":"https:\/\/alphastreet.com\/india\/kims-advancing-healthcare-in-india-through-expansion-and-medical-milestones\/","url_meta":{"origin":179948,"position":0},"title":"KIMS: Advancing Healthcare in India Through Expansion and Medical Milestones","author":"Hardik Bhandare","date":"October 10, 2023","format":false,"excerpt":"Krishna Institute of Medical Sciences (KIMS), a prominent healthcare provider in India, is making significant strides in enhancing healthcare accessibility and quality. Founded in 2000 by Dr. Bhaskar Rao Bollineni, KIMS operates multiple hospitals and healthcare facilities across several states. Their recent expansion includes a gastro sciences hospital in Vishakhapatnam\u2026","rel":"","context":"In &quot;Analysis&quot;","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/hallway-5979689_640.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/hallway-5979689_640.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/hallway-5979689_640.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":170676,"url":"https:\/\/alphastreet.com\/india\/kims-q1-fy26-earnings-results\/","url_meta":{"origin":179948,"position":1},"title":"KIMS Q1 FY26 Earnings Results","author":"Chirag Gupta","date":"August 27, 2025","format":false,"excerpt":"Krishna Medical Institution Ltd (KIMS) was Incorporated in the year 1973 and is one of the largest corporate healthcare groups in Andhra Pradesh and Telangana in terms of patients treated and treatments offered. The company offers multidisciplinary healthcare services with primary, secondary, and tertiary care across 2-3 tier cities and\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Krishna Institute of Medical Sciences Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/3-17.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/3-17.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/3-17.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/3-17.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/3-17.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/3-17.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":137905,"url":"https:\/\/alphastreet.com\/india\/krishna-institute-of-medical-sciences-limited-kims-q2-fy23-earnings-concall-transcript\/","url_meta":{"origin":179948,"position":2},"title":"Krishna Institute of Medical Sciences Limited (KIMS) Q2 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"November 11, 2022","format":false,"excerpt":"Krishna Institute of Medical Sciences Limited (NSE:KIMS) Q2 FY23 Earnings Concall dated Nov. 11, 2022 Corporate Participants: Bhaskar Rao Bollineni -- Founder and Managing Director Vikas Maheshwari -- Chief Financial Officer Abhinay Bollineni -- Executive Director and Chief Executive Officer Analysts: Bhavya Gandhi -- Dalal & Broacha Stock Broking --\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"Earnings Conference Call Transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":144228,"url":"https:\/\/alphastreet.com\/india\/examining-the-health-of-krishna-institute-of-medical-science\/","url_meta":{"origin":179948,"position":3},"title":"Examining the Health of Krishna Institute Of Medical Science","author":"Hardik Bhandare","date":"April 26, 2023","format":false,"excerpt":"\u201cThe revenue growth has to be generated from increased by volume and not by charging heavily. Volumes and not tariff should lead the growth. Under the ages of KIMS various programs were conducted to create a breast awareness program during the month of October 2022. The breast cancer day is\u2026","rel":"","context":"In &quot;Research Summary&quot;","block_context":{"text":"Research Summary","link":"https:\/\/alphastreet.com\/india\/category\/research-summary\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-6.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-6.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-6.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-6.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-6.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-6.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":129946,"url":"https:\/\/alphastreet.com\/india\/krishna-institute-of-medical-sciences-ltd-kims-q4-fy22-earnings-concall-transcript\/","url_meta":{"origin":179948,"position":4},"title":"Krishna Institute of Medical Sciences Ltd. (KIMS) Q4 FY22 Earnings Concall Transcript","author":"Staff Correspondent","date":"May 23, 2022","format":false,"excerpt":"Krishna Institute of Medical Sciences Ltd. (NSE: KIMS) Q4 FY22 Earnings Concall dated May 19, 2022 Corporate Participants: Rahul Jeewani\u00a0--\u00a0IIFL Institutional Equities -- Analyst B. Bhaskar Rao\u00a0--\u00a0Managing Director B. Abhinay\u00a0--\u00a0Chief Executive Officer Vikas Maheshwari\u00a0--\u00a0Chief Financial Officer Analysts: Praveen Sahay\u00a0--\u00a0Edelweiss Financial Services -- Analyst Anubhav Aggarwal\u00a0--\u00a0Credit Suisse -- Analyst Bhavya Gandhi\u00a0--\u00a0Dalal\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"stock earnings conference call transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/EarningsTranscript.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/EarningsTranscript.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/02\/EarningsTranscript.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":141133,"url":"https:\/\/alphastreet.com\/india\/krishna-institute-of-medical-sciences-limited-kims-q3-fy23-earnings-concall-transcript\/","url_meta":{"origin":179948,"position":5},"title":"Krishna Institute of Medical Sciences Limited (KIMS) Q3 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"February 12, 2023","format":false,"excerpt":"Krishna Institute of Medical Sciences Limited (NSE:KIMS) Q3 FY23 Earnings Concall dated Feb. 10, 2023. Corporate Participants: Bhaskar Rao Bollineni\u00a0--\u00a0Founder and Managing Director Abhinay Bollineni\u00a0--\u00a0Executive Director and Chief Executive Officer Vikas Maheshwari\u00a0--\u00a0Chief Financial Officer Analysts: Rahul Jeewani\u00a0--\u00a0IIFL Securities Limited -- Analyst Sagar Shah\u00a0--\u00a0Phillip Capital -- Analyst Piyush\u00a0--\u00a0Individual Investor -- Analyst\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"Earnings Conference Call Transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179948","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2378"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=179948"}],"version-history":[{"count":2,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179948\/revisions"}],"predecessor-version":[{"id":179951,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179948\/revisions\/179951"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125269"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=179948"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=179948"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=179948"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}